Clinical aspects on Epstein-Barr virus infection

Area of Science:

• Virology
• Immunology
• Oncology

Background:

• Epstein-Barr virus (EBV) is linked to infectious mononucleosis, Burkitt's lymphoma, and nasopharyngeal cancer.
• Atypical EBV infections can cause severe conditions like meningoencephalitis and hepatitis.
• Current treatments for EBV-associated diseases are varied and often depend on the host's immune response.

Purpose of the Study:

• To review the efficacy of antiviral treatments, particularly acyclovir, for various Epstein-Barr virus infections.
• To explore the role of host immune response in EBV pathogenesis and treatment outcomes.
• To evaluate combination therapies for severe EBV manifestations.

Main Methods:

• Review of placebo-controlled trials for acyclovir in infectious mononucleosis.
• Pilot study of combination acyclovir and prednisolone for fulminant mononucleosis.
• Analysis of treatment outcomes for EBV-associated B-cell lymphomas and hairy leukoplakia.

Main Results:

• Acyclovir showed limited clinical benefit in early infectious mononucleosis but inhibited viral replication.
• Combination therapy with acyclovir and prednisolone in severe mononucleosis led to transient viral cessation and significant symptom improvement in most patients.
• Acyclovir is effective against EBV-positive hairy leukoplakia but not X-linked lymphoproliferative syndrome.

Conclusions:

• EBV clinical manifestations are influenced by the host immune response, not solely viral replication.
• Treatment strategies for EBV disorders require personalization, often combining antiviral drugs with immunomodulatory agents.
• Further research into tailored therapeutic approaches for diverse EBV-related conditions is warranted.